Lymphedema Diagnostics Market worth $35 million by 2024

08.11.2019 - 10:47 | 1769024


Artikel von marketsandmarkets

North America to dominate the Lymphedema Diagnostics Market during the forecast period

According to the new market research report "Lymphedema Diagnostics Market by Technology (Lymphoscintigraphy, MRI, Near IR Fluorescence Imaging, Ultrasound), Disease Type (Cancer, Inflammatory Diseases, Cardiovascular, Filariasis), End User (Hospitals, Diagnostic Centers) - Global Forecasts to 2024", published by MarketsandMarkets™, is projected to reach USD 35 million by 2024 from USD 24 million in 2019, at a CAGR of 7.4%

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145177203

The increasing prevalence of lymphedema and cancer; technological advancements in diagnostic imaging modalities; and increasing investments, funds, and grants by public-private organizations are the major factors driving the growth of this market.

The lymphoscintigraphy segment accounted for the largest share of the Lymphedema Diagnostics Market in 2018.

Based on technology, the Lymphedema Diagnostics Market is segmented into lymphoscintigraphy, magnetic resonance imaging (MRI), ultrasound imaging, computed tomography (CT), X-ray lymphography, bioimpedance analysis, and near-infrared fluorescence imaging. In 2018, the lymphoscintigraphy segment accounted for the largest share of the Lymphedema Diagnostics Market. The noninvasive nature and easy reproducibility of this technology, and the fact that lymphoscintigraphy does not adversely affect the lymphatic vascular endothelium are some of the key advantages supporting the adoption of this technology.

Browse and in-depth TOC on "Lymphedema Diagnostics Market"
107 - Tables
30 - Figures
165 - Pages

The cancer segment accounted for the largest share of the Lymphedema Diagnostics Market in 2018.

On the basis of disease type, the Lymphedema Diagnostics Market is segmented into cancer, inflammatory diseases, cardiovascular disease, and other diseases (congenital abnormalities, trauma-related conditions, infections, and filariasis). The cancer segment accounted for the largest share of the Lymphedema Diagnostics Market in 2018. The large share of this segment can be attributed to the rising prevalence of cancer-associated lymphedema and increasing awareness about early disease diagnosis.



The hospitals segment accounted for the largest share of the Lymphedema Diagnostics Market in 2018.

On the basis of end user, the Lymphedema Diagnostics Market is segmented into hospitals, diagnostic centers, research & academic institutes, and other end users (pharmaceutical & biotechnology companies and CROs). The hospitals segment accounted for the largest share of the Lymphedema Diagnostics Market in 2018. The large share of this segment can be attributed to the large number of lymphedema diagnostic procedures performed in hospitals, the growing adoption of minimally invasive procedures, and the rising adoption of advanced imaging modalities to improve workflow efficiency in hospitals.

Request Research Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=145177203

The lymphedema diagnostics therapy market is segmented into four regional segments, namely, North America, Europe, the Asia Pacific, and the Rest of the World. The large share of North America can be attributed to factors such as the easy availability and rapid adoption of technologically advanced imaging systems; high incidence/prevalence of lymphedema; and the strong, well-established healthcare systems. The market in the Asia Pacific is expected to grow at the highest rate, followed by Europe.

The major players operating in the Lymphedema Diagnostics Market are GE Healthcare (US), Philips (Netherlands), and Siemens Healthineers (Germany). Other prominent players in this market include Canon, Inc. (Japan), Shimadzu Corporation (Japan), Stryker Corporation (US), Fluoptics (France), United Imaging Healthcare Co., Ltd. (China), Hitachi, Ltd. (Japan), Esaote, SpA (Italy), Neusoft Corporation (China), Mindray Medical International, Ltd. (China), Mitaka USA, Inc. (US), Curadel, LLC (US), and ImpediMed Ltd. (Australia).

Unternehmensinformation / Kurzprofil:

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.


Leseranfragen:
Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales(at)marketsandmarkets.com
PresseKontakt / Agentur:

Anmerkungen:

1769024

Kontakt-Informationen:
Vor- / Nachname: marketsandmarkets

Ansprechpartner: shelly singh
Stadt: northbook
Telefon: 18886006441

Keywords (optional):
lymphedema-diagnostics-market,

Dieser Artikel wurde bisher 61 mal aufgerufen.

Verlinkung-Tipps:



Direkter Link zu diesem Artikel:




Diese Pressemeldung bookmarken bei...


Tausendreporter BlinkList del.icio.us Folkd Furl Google Linkarena Mister Wong oneview Yahoo MyWeb YiGG Webnews Technorati

Über einen Link auf Ihrer News-, Presse- oder Partner-Seite würden wir uns sehr freuen.


Hiermit versichert der Erfasser, dass der eingestellte Artikel der Wahrheit entspricht. Er ist frei von Rechten Dritter und steht zur Veröffentlichung bereit. Die Haftung für eventuelle Folgen (z.B. Abmahnungen, Schadenersatzforderungen etc.) übernimmt der Eintrager und nicht internet-intelligenz.de


[ Anfrage per Mail | Fehlerhaften Artikel melden | Druckbare Version | Diesen Artikel an einen Freund senden ]


Alle Artikel von marketsandmarkets RSS Feed

WuXi Biologics gratuliert Tychan zum weltweit ersten Gelbfieber-Antikörper, der bei Freiwilligen erfolgreich auf Sicherheit und Wirksamkeit getestet wurde
Accord und ADIENNE schließen exklusiven Vertriebsvertrag für TEPADINA® ab
Asia Pacific Animal Health Market Trends Estimates High Demand by 2021
Mallinckrodt gibt bekannt, dass UVADEX® (Methoxsalen) in Australien für die Verwendung mit dem THERAKOS® CELLEX® Photopheresesystem für die Behandlung der chronischen Graft-versus-Host-Reaktion (cGvHR) und Hautmanifestationen von kutanen T-Zell Lympho...
3D Cell Culture Market : Regenerative Medicine to Offer Global Growth In Coming Years





Blogverzeichnis - Blog Verzeichnis bloggerei.deBlog Top Liste - by TopBlogs.de